bluebird bio and Novo Nordisk enter into research agreement to develop in vivo genome editing candidates for haemophilia and other severe genetic diseases
(WorldNews Denmark)

bluebird bio and Novo Nordisk enter into research agreement to develop in vivo genome editing candidates for haemophilia and other severe genetic diseases Cambridge, Massachusetts, US and Bagsværd, Denmark 9 October 2019 - bluebird bio, Inc. and Novo Nordisk today announced that they have entered into a three-yearresearch collaboration to jointly develop next-generationin vivo genome editing treatments for genetic diseases, including haemophilia. During the three-yearresearch collaboration, bluebird and Novo Nordisk will focus on identifying a development gene therapy candidate with the ambition of offering people with haemophilia A a lifetime free of factor replacement therapy. The research...